Comparative analysis evaluates aztreonam-avibactam efficacy against MBL-producing Enterobacterales, suggesting superior performance.
We evaluated the in vitro activity of aztreonam-avibactam and other agents against 593 metallo-β-lactamase (MBL)-producing Enterobacterales collected in France in 2024. Aztreonam-avibactam showed the highest activity (98% susceptible), with resistance mainly observed in NDM-5-producing Escherichia coli belonging to ST167, ST405, and ST361. Cefepime-zidebactam also exhibited strong activity (96.6% of susceptibility). Cefepime-taniborbactam and cefiderocol showed reduced overall activity (76.4% and 74.9% susceptibility, respectively), with reduced efficacy mainly observed among NDM-producing isolates. Comparison with 1,465 isolates from 2023 showed no increase in aztreonam-avibactam resistance.
No takes yet. Share an insight, caveat, or question.
Emeraud et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: